CSR Writing

A clinical study report (CSR) describes the conduct and results of an individual clinical trial. The CSR is a component of regulatory submissions (i.e., the Common Technical Document) and is essential for ultimate approval.

Lean CSR writing is ‘focused writing,’ followed widely across the clinical research industry.  Most CSRs are data-driven and will be authored in once the statistical analysis is completed.

Previously, CSR writing was approached as storytelling, resulting in lengthy documents with duplicate information. However, using a lean approach instead, which focuses on writing only the key messages, significantly reduces the length of CSR and decreases the time required to author and review the CSR. The lean writing approach also reduces data errors and improves the overall quality of the document.

This blog outlines three best practices to use when writing lean CSRs. 

Avoid Duplication

Information is to be stated only once in the document. Avoid redundant information.

For example, in a CSR shell, you can refer to the protocol and statistical analysis plan for the available information. You can also use Smart Templates with technical functions that enable automation and clinical content reuse to make things even easier.

Do not repeat data values presented in the source tables for CSR results. Doing so will avoid data errors and minimize the time required for quality checks. Instead, you can add the key interpretations (see next tip) and include a cross-reference to the source tables.

You should not populate in-text tables if the content and presentation are the same as the source tables; just a cross-reference to the source table is sufficient.

Refer to other sections, tables, and appendices as much as possible instead of repeating the data.

Interpret Key Results

Focus on key information and statistical results per study objectives and endpoints. A few examples are as follows:

  • Interpretation based on statistical tests, present p-values.
  • For presenting a change from baseline results, do not show the baseline and changed values. Instead, only show if an increase or decrease is observed per the values from baseline results
  • Present a trend within treatment groups. Compare the active versus placebo groups and data from different doses or treatments.
  • For safety results, common adverse events (AE), serious AEs, and AEs of special interest with cut-off % values can be presented, like ≥ 5%. The cut-off is decided based on sample size and the number of subjects experiencing AEs.
  • State if any changes in the laboratory or vital sign parameters were significant and if any AEs were reported.

Organize the Information

How information is presented significantly affects the reading experience and interpretation.

A few tips below:

  • Follow the ‘F’ pattern. Use bulleted short sentences instead of lengthy sentences.
  • Tailor or shorten source tables as in-text tables to provide the required key information.
  • State the key message first, followed by the supporting messages and reference source data.
  • Present information in a consistent order.
  • Use consistent terminology.

Ask yourself these three questions while writing to ensure the end result is an effective lean CSR:

  • Is the text really needed? Be concise!
  • Is the message and result clear and accurate?
  • Is the information well presented?

Author: Dipti Palkar, Senior Principal Medical Writer, Regulatory Medical Writing

If you need assistance with lean CSR writing or want to learn more about MMS medical writing services, read more on our website or contact info@mmsholdings.com.

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making